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Abstract: Since the mid-1980s, two lineages of influenza B viruses have been distinguished. These can
co-circulate, limiting the protection provided by inactivated trivalent influenza vaccines (TIVs).
This has prompted efforts to formulate quadrivalent influenza vaccines (QIVs), to enhance protection
against circulating influenza B viruses. This review describes the results obtained from seven phase III
clinical trials evaluating the immunogenicity, safety, and lot-to-lot consistency of a new quadrivalent
split-virion influenza vaccine (Vaxigrip Tetra®) formulated by adding a second B strain to the already
licensed TIV. Since Vaxigrip Tetra was developed by means of a manufacturing process strictly related
to that used for TIV, the data on the safety profile of TIV are considered supportive of that of Vaxigrip
Tetra. The safety and immunogenicity of Vaxigrip Tetra were similar to those of the corresponding
licensed TIV. Moreover, the new vaccine elicits a superior immune response towards the additional
strain, without affecting immunogenicity towards the other three strains. Vaxigrip Tetra is well
tolerated, has aroused no safety concerns, and is recommended for the active immunization of
individuals aged ≥6 months. In addition, preliminary data confirm its immunogenicity and safety
even in children aged 6–35 months and its immunogenicity in older subjects (aged 66–80 years).
Keywords: Vaxigrip Tetra; Influenza; Influenza vaccines
1. Introduction
Influenza is an acute viral respiratory disease caused by RNA-enveloped viruses which belong
to the family of Orthomyxoviridae and are transmitted principally through aerosols and droplets
generated by coughing and sneezing by infected people. Influenza viruses are responsible both
for seasonal influenza epidemics, especially in temperate climates, with a peak during the winter,
and sporadic out-of-season cases and outbreaks. In tropical regions, influenza outbreaks are more
irregular and influenza cases occur throughout the year [1]. Influenza involves 3–5 million people
every year worldwide [2] especially during the winter season [3]. It usually causes fever and may be
associated with headache, fatigue, muscle and joint pain, coughing, chills, and runny nose; however,
it can also lead to serious illness, such as myositis, pneumonia, encephalitis, multi-organ failure,
and fulminant disease in children [4]. Influenza is responsible for both excess hospitalization and
mortality; with between 250,000 and 500,000 influenza-related deaths every year, it places a significant
economic burden on healthcare services [5,6]. These data emphasize the importance of vaccine
prophylaxis. As life expectancy increases, and hence the proportion of elderly people, the number
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of people suffering from chronic illnesses is growing. Although influenza causes morbidity across
the age-spectrum, it is the elderly who are most vulnerable to its serious complications, such as
pneumonia [7,8]. In addition to the elderly, other groups with a higher susceptibility to developing
severe influenza and its complications (indicated as hospitalization or death) are young children,
people with pre-existing comorbidities (such as asthma, chronic lung disease, heart disease, blood and
endocrine disorders (diabetes mellitus)), and pregnant women [9]. This last group is deemed
by the World Health Organization (WHO) to have the highest priority for influenza vaccination,
since contracting influenza during pregnancy is hazardous. Indeed, pregnant women who develop
influenza illness are at risk of adverse pregnancy outcomes. Moreover, infants up to the age of 6 months
cannot be vaccinated on account of their age. Other subjects at risk of contracting influenza are those
who are frequently exposed to the virus, such as healthcare workers (HCWs) [10]. Notably, a group
that plays a significant role in the transmission of the virus within the community is that of children
attending day-care centers and schools (Figure 1) [11].
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can occur in the case of co-infection. In this case, a virus endowed with novel antigenic properties 
could cause pandemics if it is able to replicate in humans. Pandemics have been described since the 
middle of the 18th century, and occur at intervals of 10–40 years [12]. Influenza B viruses is common 
in children, young adults, and the elderly, and causes seasonal epidemics every 2–4 years. However, 
limited data regarding its impact in adults and its clinical burden are currently available. It is 
characterized by a slow mutation rate. While it can occasionally infect seals, it does not have a 
domestic animal reservoir [13]. Influenza A and B are not clinically distinguishable [14]; however 
there is a general conviction that the former is responsible for more serious influenza cases than the 
latter. This is probably why researchers have seldom focused on influenza B, as is demonstrated by 
the scarcity of data on its epidemiology and burden [15]. 
Influenza is a vaccine-preventable disease, and vaccines constitute the most effective strategy 
for the prevention and control of seasonal influenza virus infections and for reducing influenza-
related morbidity and mortality [16]. The elevated rate of mutation that characterizes influenza 
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Two influenza virus subtypes can cause infection in humans: type A and type B. The former causes
the highest number of seasonal influenza infections; in addition to humans, also domestic animals,
such as pigs, birds, and horses, can constitute the reservoir for the virus, wherein re-assortment events
can occur. More specifically, re-assortment among different i fluenza A virus s can occur in the case of
co-infection. In this case, a virus endowed with novel antigenic properties could cause pandemics if it
is able to replicate in umans. Pandemics have been described since the middle of the 18th ce tury,
and occur at intervals of 10–40 years [12]. Influenza B viruses is co mon in children, young adults,
and the elderly, and causes seasonal epidemics every 2–4 years. However, limited data regarding its
impact in adults and its clinical burden are currently available. It is characterized by a slow mutation
rate. While it can occasionally infect seals, it does not have a domestic animal reservoir [13]. Influenza A
and B are not clinically distinguishable [14]; however there is a general conviction that the former is
responsible for more serious influenza cases than the latter. This is probably why researchers have
seldom focused on influenza B, as is demonstrated by the scarcity of data on its epidemiolog and
burden [15].
Influ nza is a vacci e-preventable disease, and vaccines constitute the most effective strategy for
the prevention and control of seasonal influenza virus infections and for reducing influenza-related
morbidity and mortality [16]. The elevated rate of mutation that characterizes influenza viruses could
allow the emergence of new antigenic variants with the ability to evade the immunity induced by
previous vaccinations or infection processes, thereby facilitating transmission among humans [17].
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For this reason, in order to ensure matching between the viruses most likely to circulate in the upcoming
season and the strain present in the vaccine, the process of selecting the viral strain to be included in
the seasonal vaccine is performed by the WHO on the basis of information on human influenza virus
epidemiology provided by the Global Influenza Surveillance Network (GISN). This process has been
carried out since 1971, and in 1998 its frequency was increased from once to twice per year, in order to
provide separate recommendations for each hemisphere (in February in the northern hemisphere [18]
and in September in the southern hemisphere [19]). These recommendations are issued about 9 months
before the vaccine is administered to the population, in order to allow enough time for the manufacture
and distribution of the vaccine. Significant efforts have been made by the WHO Global Influenza
Surveillance and Response System (GISRS) and its partners to improve this process of assessment [20].
Until 1978, seasonal influenza vaccines included only two strains (one of type A influenza and one of
type B); since then, vaccine complexity has increased. Two influenza type A subtypes (A/H1N1 and
A/H3N2 strains) and one B strain (belonging to B/Yamagata or B/Victoria lineages) constitute the
traditional seasonal influenza vaccines, defined as Trivalent influenza vaccines (TIVs) [21]. Currently,
TIVs account for the majority of seasonal influenza vaccines.
Since 1985, two antigenically distinct phylogenetic lineages (the Victoria and Yamagata
lineages) [22] have diverged from influenza B viruses. Until that year, a single influenza B lineage was
present globally, which was the precursor of the Yamagata lineage.
By 1975, the Victoria lineage had developed in China from a minor lineage of B viruses, although it
was not isolated outside the country until 1985 [23]. From 1987 to 1989, it was the prevalent lineage
worldwide, and re-emerged in 2001–2002. From then on, it has co-circulated globally with the Yamagata
lineage, as in the US since 2001 [24], in variable and unpredictable proportions among regions and
seasons [25]. During the 2007–2008 influenza season, when the B viruses co-circulated worldwide,
higher mortality rates were reported in the US, as were excess hospitalization rates in children between
0 and 4 years of age [26]. Recently, influenza B viruses have constituted a significant cause of flu,
accounting for about 23% of the circulating strains around the world and even reaching 90% during
some seasons, thus contributing significantly to influenza morbidity [27]. In each influenza season,
one of the two B lineages may be prevalent over the other, making it very difficult to predict the
predominant B lineage to be included in the next seasonal vaccine [26,28]. The terms match/vaccine
match and mismatch/vaccine mismatch are related to the level of similarity or difference among
the predominant circulating lineage and the strains included in the vaccines. In the case of vaccine
mismatch, this evolution of influenza viruses has reduced vaccine protection, owing to the limited or
absent cross-lineage protection elicited by TIVs [29].
It has been estimated that, between 2000 and 2013, discrepancies between the circulating B lineage
and that present in the vaccine formulation occurred in about one-quarter of seasons in which influenza
B caused more than 10% of influenza cases [27,30–32]. Moreover, eventual cross-protection is estimated
to be low in the event of mismatch, owing to the great antigenic difference between the two influenza
B lineages [33]. For instance, the efficacy of the B lineage vaccine, which is predicted to be 71–77%
when circulating influenza B and B vaccine strains match, drops dramatically (46–49%) in the case of
mismatch, significantly limiting the protective effects of TIVs [34], mainly in high-risk groups, such as
the elderly, as reported by the group of De Jong [35] during the major epidemic A(H3N2) virus strain.
These data underscore the need to broaden protection by using quadrivalent influenza vaccines
(QIVs) [25], as was proposed by the US FDA in 2007 [36]. Since 2012, QIVs have been commercially
available in various formulations (such as split, subunit, and live attenuated influenza (LAIV)
formulations) and are substituting the corresponding TIV composition throughout the world.
QIV overcomes the risk of low antigenic matching between the vaccine strains and circulating viruses,
since it contains two influenza B strains and may confer greater protection than the traditional TIV.
This could allow both hospitalization and mortality to be reduced [33] and, even if the cost of QIV
is higher than that of TIV, replacement of the latter would be significantly cost-effective both for
society and for third parties [37]. This result has been confirmed by a study by the group of de Boer,
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which estimated the substantial cost-effectiveness of replacing TIV with QIV, with a net societal budget
impact of $5.8 billion in the US and a 27.2% reduction in influenza cases caused by B lineages in the
next two decades [38]. QIVs were first introduced in the US [39], and subsequently became part of
the immunization strategies of several countries. Concerning the US, during the current influenza
season (2017–2018) both TIV and QIV are available, and the Advisory Committee on Immunization
Practices (ACIP) recommends annual vaccination for all subjects ≥6 months of age who do not have
contraindications. By contrast, it does not recommend the use of LAIV (administered as a nasal spray
flu vaccine), owing to concerns regarding its effectiveness against (H1N1)pdm09 viruses during the
2013–14 and 2015–16 seasons [40].
2. Evaluation of Influenza Vaccine Efficacy: From CHMP Criteria to Post-CHMP Criteria
The efficacy of influenza vaccines is traditionally evaluated by means of serological assays that identify
influenza-specific serum antibodies induced by the vaccine itself as correlates of protection [41]. These consist
of the single radial hemolysis assay (SRH) [42] and hemagglutination inhibition assay (HI) [43].
The SRH assay enables antibodies to be quantified by measuring hemolysis areas [44,45], which are
proportional to the antibody concentration, since they result from the binding between the antigen
and the antibody. The assay is rapid, easily reproducible, and reliable, and also allows a high number
of samples to be analyzed; for this reason, it is notably appropriate for large-scale studies, particularly
epidemiological investigations [46,47].
The HI assay is also a relatively simple test to automate. It is based on erythrocyte agglutination
due to the binding of the viral surface protein hemagglutinin (HA) to sialic acid sites on the surface
of red blood cells, thereby ensuring the internalization of the virus. The HA content is correlated
with the number of agglutinated erythrocytes [44]. The erythrocytes commonly used are of avian
origin (chicken or turkey) or mammalian origin (horse or guinea pig). HI titers are quantified as the
reciprocal of the highest serum dilution (titer) (1/dilution factor) that inhibits hemagglutination by
binding with the virus. Hemagglutination is inhibited or blocked when the antibodies recognizing
HA are present in the serum in a sufficient number [48]. One drawback to both SRH and HI is that
they are not standardized tests, and display significant inter-laboratory variability; for this reason,
in clinical development programs, both tests should be performed in designated and properly qualified
laboratories [49].
The microneutralization (MN) assay, also known as the Virus Neutralization (VN) assay, is not
compulsory for influenza vaccine licensure. However, it is strongly recommended that it should
be performed at least in a representative subpopulation of clinical trial participants, if not in all.
MN detects the antibodies capable of neutralizing the ability of the virus to enter or replicate in
mammalian cells. The MN assay also identifies those antibodies that recognize neuraminidase (NA).
For this test, the antibody titer is expressed as the reciprocal of the highest serum dilution that causes
at least 50% of cytopathic effect in mammalian cell cultures. Madin–Darby canine kidney (MDCK) cells
are usually used [50]. Although MN is an adequate substitute for HI, the best protocol for performing
the MN test has not yet been established. Whereas no correlates of protection have yet been established
for MN, an SRH titer of ≥25 mm2 and an HI titer of ≥1:40 are considered to be associated with 50% or
higher protection against influenza [46] and represent the thresholds that have to be met for licensing
of the vaccine in Europe [51].
Three criteria have been identified by the Committee for Medicinal Products for Human Use
(CHMP). The percentage of vaccines presenting an HI titer ≥ 40 or SRH > 25 mm2 should be >70% in
subjects aged 18–60 years and >60% in the over-60s. The seroconversion rate (SCR) (at least a 4-fold
increase in titer) should be >40% in 18–60-year-olds and >30% in the over 60s. A mean geometric
increase (ratio of pre- to post-vaccination) of >2.5 is required in 18–60-year-olds and >2 in over-60s.
Regarding the US, the FDA applies the same criteria, but the lower bound of the 95% confidence
interval (CI) must be higher than or equal to that of the SCR and geometric mean titer (GMT) criteria
(Table 1) [52].
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Table 1. Criteria established by EMA for the licensing of influenza vaccines.
Ema Criteria for Influenza Vaccine Licensing
Seroconv. Rate or Sig. Incr. % >30.00 ELD–>40.00 ADU
Mean Gmt Increase >2 ELD–>2.5 ADU
Seroprotection Rate % >60.00 ELD–>70.00 ADU
Abbreviations: ADU: Adults; ELD: Elderly; EMA: European Medicine Agency; Seroconv. rate or sig. incr.:
Seroconversion rate or significant increase; GMT: Geometric Mean Titer.
At least one of the criteria mentioned above has to be met for the annual licensing of seasonal
vaccines and all three criteria for pandemic vaccines. However, these criteria present limitations.
They were established decades ago on the basis of a limited number of investigations performed in
healthy adults, whereas high-risk groups, such as children, were not included in these evaluations.
The neonatal immunological response to vaccines is weak; in more detail, the neonatal immune
system is biased against Th1 responses, supposedly to prevent a pro-inflammatory immune response
towards the maternal tissues that could cause preterm birth or spontaneous abortion [53]. Furthermore,
newborns show an impaired humoral response responsible for a qualitatively and quantitatively lower
antibody production respect to older infants and CD4 lymphocyte responses are often weaker and
less sustained than those of adults [54]. Concerning the immune response upon influenza vaccination
in children, a correlation between an increased antibody production and age has been reported [55].
Furthermore, conversely from vaccinated adults, children are characterized by poor cross-reactivity in
case of influenza B virus vaccine-mismatch [56].
Regarding the elderly, a progressive decline in the humoral and cellular immune responses
(a phenomenon also referred to as “immunosenescence”) towards infections and vaccinations is
observed [57]. Several extrinsic (such as co-morbidities and stress) and intrinsic (genetic background)
factors can exert an effect on it [58]. In the elderly, the vaccine immune response is diminished
respect younger adults [59] with an effectiveness reduced of 50% also in presence of elevated influenza
vaccination rate and well-matched vaccine [60,61]. Subjects with a reduced health status present a
defective number and function of Natural Killer (NK) cells that are positively associated with low HI
titers in vaccinated older subjects [62,63]. In addition, older individuals show a defective differentiation
and function of B and T lymphocytes, reduced antibody production as well as costimulatory molecule
CD28 expression on T lymphocytes [64–68].
The evaluation of the efficacy of LAIV cannot be properly performed through serological assays.
This has led to changes in the assessment of influenza vaccines in Europe since 2014 [69]; these have
promoted a more global view of vaccine immunogenicity, which includes not only the evaluation of HI
titers, but also the evaluation of MN titers and techniques used for the quantification of cell-mediated
immunity (CMI), through flow cytometry. CMI is performed in a randomly selected subset of the
subjects included in the clinical trial, and is encouraged especially in the elderly (≥75 years old) since
it is associated with the establishment of protection related to humoral immunity. Indeed, although
the elderly may present higher HI and MN antibody titers than young adults, these titers might not be
correlated with protection [70].
The advantage of flow cytometry is that it can evaluate vaccine efficacy by simultaneously
characterizing lymphocyte phenotype and responses upon vaccination in a heterogeneous cell
population. This is achieved through the use of fluorescent-labeled antibodies to detect specific
proteins that can be expressed on the surface of the cells or intracellularly. It is recommended that T-cell
immune responses be investigated as well as the activation of CD4, CD8, and memory B lymphocytes,
since they can provide more information regarding both immune responses and protection elicited by
influenza vaccination. However, the choice of which populations to analyze is not simple. Moreover,
no correlates of protection concerning cell populations following vaccination are yet available and
results can be difficult to interpret [71].
Other widely used methods of evaluating lymphocyte functions are ELISA [72] and ELISPOT [73]
for the detection of cytokine responses, 3H-thymidine incorporation or carboxyfluorescein succinimidyl
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ester CFSE for the assessment of T-cell proliferation upon encountering an antigen, chromium release
assay for the determination of antigen-specific cytotoxicity, and the investigation of differential
gene or microRNA expression. In recent years, several new T-lymphocyte methods, including the
improved FLUOROSPOT ELISPOT assay, and novel techniques such as cytometry by time-of-flight
mass spectrophotometry (CyTOF) have been developed. Whereas the former is able to detect multiple
cytokines in the same well, the latter assesses more than 50 parameters concurrently. Currently,
despite the availability of several assays for the assessment of cellular immunity, no correlates of
protection have so far been established for these techniques, which, in addition, display marked
inter-laboratory variability, not least because of the absence of standardized protocols [3].
3. General Information on QIV
In recent years, the efficacy of several QIVs has been investigated. The group of Domachowske [74]
reported that QIV was not less immunogenic than TIVs in children aged from 3 to 17 years. TIVs have
proved able to induce some degree of cross-reactivity against B strains, though less antibody production
has been observed for the unmatched strains than for the matched strains. Furthermore, for the
unmatched strains, all EMA criteria have not been met by TIVs [33,75–77].
4. A Novel Quadrivalent Inactivated Influenza Vaccine: Vaxigrip Tetra
Vaxigrip Tetra® (Sanofi Pasteur) is a novel four-strain influenza vaccine belonging to the Vaxigrip®
family of influenza vaccines [78]. It is a quadrivalent split-virion inactivated influenza vaccine
containing the purified HA and NA antigens from the four influenza virus strains recommended by the
WHO [79]. The total amount of HA glycoprotein contained in Vaxigrip Tetra is 60 µg. The viral growth
of the strains constituting Vaxigrip Tetra, as well as the corresponding TIV (Vaxigrip®, Sanofi Pasteur,
Lyon, France) formulated with two A strains (A/H1N1 and A/H3N2) and a single B strain and
containing a total amount of 45 µg HA glycoprotein, is conducted in embryonated chicken eggs.
Following the collection, clarification, and concentration of the allantoic fluid, the viral particles
are purified and split by means of the detergent octoxynol-9. Finally, inactivation by means of
formaldehyde is performed in order to obtain 4 monovalent bulks for each strain, which are formulated
into a sterile suspension of phosphate buffered saline without preservatives [80].
4.1. Clinical Trials Performed on Vaxigrip Tetra
The immunogenicity and safety of Vaxigrip Tetra have been investigated in six phase III
clinical trials in subjects aged ≥3 years and in one recent phase III clinical study conducted on
children aged 6–35 months (Table 2). Three of these studies were considered pivotal investigations,
since their aim was to characterize Vaxigrip Tetra immunogenicity for approval in the EU [81–83].
The licensed Vaxigrip Tetra formulated through a revised process was evaluated by these three main
trials [81–83] and by another involving adults aged 18–60 years [84]. Two phase III clinical trial were
considered supportive; these were conducted on adults, the elderly and children from 9 years of age,
and investigated Vaxigrip Tetra batches produced with the same method as Vaxigrip [85,86]. A further
randomized double-blind placebo-controlled trial involving children aged from 6 to 35 months was
concluded recently, and preliminary data concerning this group are available [87]. The safety profile
was investigated collecting unsolicited adverse events (AEs) and serious adverse events (SAEs)
in accordance with International Conference on Harmonization E2A Guideline for Clinical Safety
Data Management: Definitions and Standards for Expedited Reporting [88]. The term AE indicates
“any untoward medical occurrence which occurs during administration of a vaccine or follows immunization
and which does not necessarily have a causal relationship with the use of the vaccine”. The AE could be any
unfavorable or unintended sign, an abnormal laboratory finding, a symptom or a disease”. The term
SAE indicates “A serious adverse event (experience) or reaction is any untoward medical occurrence that at any
dose results in death or is life-threatening” [88]. SAEs have to be compulsorily notified [89].
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Table 2. Phase III clinical trials conducted on Vaxigrip Tetra.
Phase III Clinical Trials on Vaxigrip Tetra
Clinical Trial
Registry No. Study Design Type of Study Objectives Age Participants Countries
Influenza
Season Results Ref.
GQM02
EudraCT No.
2011-005374-33
Randomized,
double-blind,
active-controlled,
multi-center study
Pivotal
investigations
testing the QIV
licensed
Primary Objective:
-Non-inferior immunogenicity
of QIV to each TIV for the
shared strains
Secondary Objective
-Humoral immune response
induced by QIV
-Superior immunogenicity of
QIV to each TIV for the
alternate B strain-Safety
3–8 y
1242 participants
immunized with:
-QIV (n = 887 *),
-TIV-1 with B/Vic (n = 181 *),
-an investigational TIV-2 with
B/Yam (n = 174 *)
* 65 subjects in the QIV group
and 31 in the TIV groups
were at-risk condition
Finland,
Poland,
Mexico
and
Taiwan
2013/2014
NH
Comparable immunogenicity of
QIV vs. TIVs for the shared
strains, and superiority for the
additional B strain.
Safety of QIV.
Comparable immune responses
induced by QIV in at-risk
subjects with underlying
comorbidity respect to the
overall population after
vaccination with QIV
[82]
GQM09
WHO
Universal
Trial No.
U1111-1127-7693
Open-label,
uncontrolled
Pivotal
investigations
testing the QIV
licensed
Primary Objective:
-Immunogenicity
-Safety
9–17 y 100 subjects immunized with:QIV Taiwan
2013–2014
NH
Immunogenicity and safety
demonstrated in
children/adolescents
[81]
GQM11
EudraCT No.
2014-000785-21
Randomized,
multicenter,
double-blinded for
the QIV and
TIV-2 groups,
single-blinded for
the TIV-1 group
Pivotal
investigations
testing the QIV
licensed
Primary Objective:
-Similar immunogenicity of 3
QIV lots
-Non-inferiority of QIV respect
to TIV for the shared strains
Secondary Objective
-Superior immunogenicity of
QIV respect to TIV for the
additional strain in each
age group
-Safety
≥18 y
2225 subjects (1114 adults
(18–60 y) and 1111 subjects
(>60 y) randomized 2:2:2:1:1
to receive:
-a single dose of one of three
lots of QIV,
-the licensed TIV with
B/Yam,
-an investigational TIV with
B/Vic
Belgium,
France,
Germany,
Poland
2014–2015
NH
Lot-to-lot consistency
demonstrated.
Non-inferiority demonstrated
between QIV and TIV.
Higher immunogenicity of QIV
against alternate B strains.
Similar safety profile of QIV as
the licensed TIV
Comparable response in
at-risk subjects
[83]
GQM07
NCT02550197
Observer-blind,
randomized,
controlled,
multicenter
Evaluation of the
QIV licensed
Primary Objective:
-Immunogenicity
-Safety
18–60 y
300 subjects immunized with:
-QIV (n = 200)
-TIV (n = 100)
Korea 2015–2016NH
Immunogenicity and safety
demonstrated in adults [84]
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Table 2. Cont.
Clinical Trial
Registry No. Study Design Type of Study Objectives Age Participants Countries
Influenza
Season Results Ref.
Phase III Clinical Trials on Vaxigrip Tetra
GQM04
NCT01481454
Randomized,
active-controlled,
multicenter,
double-blind for
QIV lots, open-label
for QIV vs. TIV
Supportive
testing QIV
batches produced
with the TIV
process
Primary Objective:
-Safety of QIV and TIV
Secondary Objective
-Immunogenicity of QIV
accordingly with EMA criteria
-Immunogenic equivalence of
three lots of QIV
-Immunogenicity in
children/adolescents
9–60 y
2090 subjects:
-QIV (n = 1977) (1648 adults
and 329
children/adolescents)
-TIV (n = 111) (56 adults and
55 children/adolescents)
Australia,
Philippines
2011/2012
NH and
2012 SH
Lot-to-lot consistency
demonstrated.
EMA criteria met in
9–60 years old.
Comparable response and safety
profiles of QIV to TIV
[86]
GQM01
EudraCT:
2011-001976-21
Randomized,
active-controlled,
multicenter
Supportive
testing QIV
batches produced
with the TIV
process
Primary Objective:
-Non-inferiority of QIV respect
to a licensed TIV and an
investigational TIV
Secondary Objective
-Safety
-Superior ab response to each B
strain in the QIV group respect
to the corresponding B strain
in TIV group lacking this strain
≥18 y
1565 participants:
-QIV (n = 1116 subjects),
-licensed TIV with B/Vic
(n = 226),
-the investigational TIV with
B/Yam (n = 223)
France,
Germany
2011–2012
NH
Safety of QIV and superior
immunogenicity of QIV respect
TIV for the unmatched strains
and non-inferiority for the
matched strains
[85]
GQM05
EudraCT:
2013-001231-51
Randomized,
double-blind
(except TIV groups
open-label),
placebo-controlled,
multicenter
Pediatric
investigation
Primary Objective:
-Efficacy to prevent at least one
of the following endpoints:
• laboratory-confirmed
influenza illness due to any
influenza circulating strain
(A or B types)
• laboratory-confirmed
influenza illness caused by
influenza strains similar to
those contained in the vaccine
Secondary Objective
-Non-inferiority of QIV vs. TIV
as well as superior
immunogenicity for B strains
-Safety
6–35 m
5805 participants:
-QIV (n = 2721 subjects),
-placebo (n = 2715),
-licensed TIV with B/Vic or
B/Yam (n = 369)
Europe,
Asia, Latin
America,
South Africa
2014–2015
NH
TIVYAM or
TIVVIC
Preliminary results:
Immunogenicity of QIV
Prevention of influenza caused
by strains similar to the vaccine
strains and any
circulating strains
Protection against severe
influenza illness and reduced the
risk for AOM and ALRI
associated with influenza
Reduction of other relevant
clinical outcomes for children,
including medical visits and
antibiotic use
Safety
[87]
Abbreviations: Ab: antibody; EMA: European Medicine Agency; m: months; NH: Northern hemisphere; SH: Southern hemisphere; Vic: Victoria; y: years; Yam: Yamagata; *: subjects
at-risk condition.
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4.1.1. GQM01 Clinical Trial in Adults
Pépin and coll. [85] conducted a phase III, randomized, active-controlled, multicenter trial in
Germany and France (GQM01; EudraCT No. 2011-001976-21) in two subgroups of healthy adults
(18–60 and >60 years) during the 2011/2012 influenza season. The aim of the study was to demonstrate
the non-inferiority of QIV in inducing antibody production in comparison with the 2011–2012
licensed TIV (containing the B/Brisbane/60/2008 strain, belonging to the Victoria lineage) and an
investigational TIV containing the alternative B strain lineage (B/Florida/04/2006, Yamagata lineage).
The secondary objective was to evaluate the safety profile of the vaccines, including potentially
SAEs. AE of special interest (AESI) were represented by anaphylaxis, Guillain–Barré syndrome,
encephalitis, myelitis, neuritis, convulsions, and vasculitis and, as well as AEs, were classified by
the investigator as related or unrelated to vaccination. Secondly, the putative superiority of B-strain
immune responses induced by QIV in comparison with TIV not containing the matched B strain
was also investigated. To this end, 1116 subjects were vaccinated with QIV, 226 with the licensed
TIV, and 223 with the investigational TIV. HI titers were evaluated pre-vaccination and 21 days
post-vaccination; in all groups, comparable pre-vaccination HI antibody titers were observed which
increased upon vaccination. In comparison with TIV, QIV was able not only to induce non-inferior
antibody responses against all four matched strains, but also to promote greater antibody production
than the TIVs lacking the corresponding B strain for both B strains in both age-groups. For all
four vaccine strains, QIV met EMA criteria in both age-groups. Furthermore, for the three vaccines,
the younger age-group generally showed higher post-vaccination GMT ratios and response rates than
elderly adults [85]. This finding is in agreement with other studies, and is ascribed to the waning
responsiveness of the elderly immune system and to other age-related factors [90,91]. Concerning TIVs,
EMA criteria were met for the A strains and the matched B strains, but not for the unmatched B strains.
Regarding safety, similar solicited reactions (usually injection-site pain, headache and myalgia
resolved within 3 days of vaccination), unsolicited AEs, and SAEs were reported in the QIV and
pooled TIV groups. Nasopharyngitis (1.1% vs. 0.9% for subjects immunized with QIV and TIV,
respectively) and injection-site pruritus (1.3% vs. 1.1% for individuals receiving QIV and TIV,
respectively) constituted the most common vaccine-related AEs. Neuritis was the single AESI reported
in a TIV vaccinated elderly subject, but it was classified as not treatment-related. No vaccine-related
SAEs or deaths were observed [85].
4.1.2. GQM04 Clinical Trial in Children, Adolescents, and Adults
A phase III randomized, controlled, multicenter trial conducted in Australia and in the Philippines
in 2012 (GQM04; NCT01481454) investigated the safety, immunogenicity and lot consistency of Vaxigrip
Tetra in children/adolescents (9–17 years, n = 329) and adults (18–60 years, n = 1648) in comparison
with licensed TIV (children/adolescents n = 55; adults n = 56) [86]. The study recruited children,
adolescents, and adults who had not been immunized with influenza vaccine containing the 2012
Southern Hemisphere formulation or a 2011–2012 Northern Hemisphere formulation within 6 months
before enrollment or any other vaccine during the previous 4 weeks. Investigation of immunogenicity
(evaluated by means of HI and MN) and safety profiles confirmed the comparability of QIV and TIV,
in agreement with previous results [85]. EMA criteria were met in adult groups for all four strains
contained in QIV; in addition, the antibody response seen in the group of children/adolescents was
superior to that recorded in adults, though EMA criteria have not yet been established for the former.
In addition, QIV lot-to-lot equivalence among the three lots examined for all four strains and in
both age-groups was demonstrated, supporting the conviction that Vaxigrip Tetra can be produced
consistently across seasons and producers [86]. Equivalent solicited reactions, unsolicited AEs,
and SAEs were observed between TIV and QIV recipients in both age groups. Vaccine-related SAEs or
deaths were not reported [86].
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4.1.3. GQM02 Clinical Trial in Children (3–8 Years)
A subsequent phase III randomized, double-blind, active-controlled, multi-center study conducted
in Finland, Poland, Mexico, and Taiwan on 1242 children aged 3 to 8 years during the 2013/2014
Northern Hemisphere influenza season (GQM02; EudraCT No. 2011-005374-33) investigated the
immunogenicity and the safety profile of Vaxigrip Tetra (which contained the 4 Northern Hemisphere
2013/2014 influenza strains recommended by the WHO and the EU) in comparison with its trivalent
counterpart 2013–2014 formulation (TIV-1, Vaxigrip®), which contained both A strains and the B
Victoria lineage strain, and an investigational TIV (TIV-2) containing both A strains and the B Yamagata
lineage strain [82]. HI titers at the baseline (indicated as day 0) and 28 days after the last vaccination
were measured in order to evaluate antibody responses induced by QIV and by TIVs. The acceptability
of the QIV safety profile and the non-inferiority of this vaccine to TIV for the shared strains were
confirmed. In addition, it was observed that QIV displayed higher immunogenicity towards influenza
B strains than a TIV formulated with the alternative B strain lineage. In detail, although the HI antibody
titers were relatively high at the baseline, probably as a consequence of natural exposure to the same
strains or to one similar to those contained in the QIV formulation, GMTs were enhanced at least
6-fold for all vaccine strains upon QIV immunization [82]. Seroprotection against all the strains was
achieved in almost all vaccines [82], whereas seroconversion rates were similar to those found by
Cadorna [86] in children and adolescents aged from 9 to 17 years, ranging from 64.8% to 88.5% for all
four strains [82].
Regarding the safety profile, 62.4% of QIV and TIV recipients notified solicited injection-site
reactions; pain was the most frequently reported solicited reaction in both groups. Regarding solicited
systemic reactions, they were reported by 48.9% and 45.5% of subjects immunized with QIV and TIV,
respectively, with malaise representing the most common solicited systemic reaction, followed by
myalgia and headache. No significant difference was observed in the rates, types, or severity of
solicited reactions between QIV and TIV groups, and they were classified as grade 1 (mild) and
resolved within 3 days or less by their onset. An unique AESI of severe thrombocytopenia was
observed 9 days after a first vaccination in one 3-year-old subject receiving QIV and it resolved after
38 days; it was considered vaccine-related due to the temporal relationship with the immunization [82].
4.1.4. GQM09 Clinical Trial in Children and Adolescents
The aim of the open-label phase III study (GQM09; U1111-1127-7693) was the assessment of
the immunogenicity (evaluated through HI) and safety of the 2013–2014 Northern Hemisphere
QIV formulation in 100 children and adolescents 9–17 years of age enrolled in Taiwan [81].
Although pre-vaccination titers were relatively high, post-vaccination HI titers enhanced for all four
strains. Following vaccination, seroprotection rates reached 99% for A/Texas/50/2012 (H3N2) and
100% for A/California/7/2009 (H1N1) pdm09, B/Massachusetts/2/2012, and B/Brisbane/60/2008.
Rates of seroconversion/significant increase of HI titer were relatively low due to the elevated
pre-vaccination titers. The most common solicited reactions were injection-site pain (56%), myalgia
(45%), and malaise (15%) which in general were mild or moderate. No treatment-related AEs,
immediate unsolicited AEs, unsolicited non-serious injection-site AEs, grade 3 unsolicited AEs,
or SAEs were notified. The present clinical trial demonstrated that QIV was immunogenic and
well tolerated [81].
4.1.5. GQM11 Clinical Trial in Younger and Older Adults
The aim of a pivotal multicenter phase III study (GQM11; EudraCT No. 2014-000785-21) [83]
was to evaluate the safety, immunogenicity (through HI and serum neutralization assays on D0 and
D21) and lot-to-lot consistency of the 2014–2015 Northern Hemisphere formulation of Vaxigrip Tetra
in comparison with a licensed TIV containing B Yamagata and an investigational TIV containing
B Victoria. The study involved a total of 2225 subjects (1114 adults (18–60 years) and 1111 subjects
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(>60 years)) in three centers in Belgium, three in France, four in Germany, and five in Poland from
September 2014 to October 2015 [83]. More in detail, 1024 subjects (18–64 years), 629 (65–84 years),
and 13 (over 85 years) were immunized with QIV; whereas 348 (18–64), 201 (65–84), and 4 (over 85)
received TIV [92].
This study also confirmed lot-to-lot equivalence (statistical equivalence of post-vaccination HI
GMTs among the three QIV lots) and the non-inferiority of HI titers for the A strains and for the
B strain when the comparator TIV was present; furthermore, the antibody response to the B strain
lineage was even higher when the comparator TIV was absent (Figure 2). These results met EMA
criteria for the licensing of influenza vaccines [67] and they were in line with those obtained from
a previous study on younger adults immunized with the 2011–2012 formulation [85]. Investigating
the patients 66–80 years, the analysis of HI antibody responses revealed that seroconversion rates and
geometric mean increase met EMA criteria in adults aged 66–80 years for all the strains evaluated,
although elevated seroprotection was observed on D0. These data strongly support the use of Vaxigrip
Tetra in older adults (60–80 years), too, who constitute one of the highest-risk groups [93].
Good protection towards all four strains was also achieved in subjects presenting high-risk
conditions; furthermore, seroprotection rates remained high one year after vaccination (≥98% in
younger adults and ≥90% in older adults) [83].
In an investigation of SN responses conducted in a subset of vaccines according to EMA guidelines
on influenza vaccines [94], a strong correlation was found between SN titers and protection against
all four vaccine strains and between SN and HI antibody titers [83]. Concerning the safety profile,
in agreement with previous studies [85,86,95], Vaxigrip Tetra proved to be well tolerated and displayed
a similar safety profile to that of Vaxigrip [83]. In greater detail, solicited reactions, represented
principally by injection-site pain, headache, malaise, and myalgia, were mainly grade 1 and resolved
within 3 days. In both TIV and QIV vaccines, older adults showed lower solicited reaction rates than
younger adults. Any vaccination-related SAE was notified [83].
4.1.6. GQM07 Clinical Trial in Adults
An observer-blind, randomized, controlled, multicenter trial compared the immunogenicity and
safety of the Northern Hemisphere 2015–2016 formulations of Vaxigrip Tetra with those of the licensed
TIV in 300 Korean adults aged 18–60 years (GQM07; ClinicalTrials.gov No. NCT02550197) [84]. In that
study, too, elevated pre-existing antibodies were observed in most participants, and increased by at
least 4-fold upon QIV vaccination. The elevated immunogenicity measured by means of HI assay
revealed that the ratio between the post-/pre-vaccination geometric mean of HI titers was≥3.97, with a
seroconversion rate of≥40% for all strains with the exception A/H1N1 (39.7%). Equivalent results were
obtained for the three strains contained in TIV. The immunogenicity of QIV towards the alternative B
strain (Victoria) was superior to that of TIV. QIV also showed an acceptable safety profile, similar to
that of TIV. More specifically, injection-site pain, myalgia, malaise, and headache represented the
most common solicited reactions to QIV and TIV. Solicited reactions were mainly grade 1, and few
participants developed grade 3 (severe) reactions (<2% per reaction type). All solicited reactions
resolved within 5 days or less [84].
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4.1.7. GQM05 Clinical Trial in Children (6–35 Months)
Data regarding the clinical efficacy of Vaxigrip Tetra in unvaccinated children between 6 and
35 months of age were recently obtained from a large-scale, placebo-controlled phase III trial (GQM05,
EudraCT: 2013-001231-51) performed in Europe, Asia, Latin America and South Africa, and presented
at the Sixth ESWI Influenza Conference (2017) in Riga, Latvia [87]. The study was requested by
EU health authorities as part of pediatric development. The efficacy trial in the youngest children
aimed to reinforce the product profile and to demonstrate the efficacy of the product in a highly
vulnerable population.
A total of 5805 children who had never been immunized were enrolled from March 2014 to
December 2015. Children were stratified to include equal numbers of subjects immunized with
2 doses 0.5 mL of Vaxigrip Tetra (n = 2721) or placebo (n = 2715); in addition, 369 subjects received
NH 2014–2015 TIVYAM or TIVVIC. Influenza cases were confirmed through viral culture and reverse
transcription polymerase chain reaction (RT-PCR). Severe laboratory-confirmed influenza illness was
associated with at least one of the following symptoms: fever >39.5 ◦C in children aged <24 months
or ≥39.0 ◦C in those aged ≥24 months, and/or at least one significant influenza like illness (ILI)
symptom that prevented daily activity (cough, nasal congestion, rhinorrhea, pharyngitis, otitis,
vomiting, diarrhea), and/or associated to one of the following events: acute otitis media (AOM),
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acute lower respiratory infection (ALRI). In this age-group, too, QIV promoted elevated immune
responses towards the 4 strains included in the vaccine, thereby highlighting the broader protection
against both B lineages offered by QIV in comparison with TIV.
Vaxigrip Tetra was protective towards laboratory-confirmed ILI caused not only by strains similar
to the vaccine strains, but also by any circulating strains, supporting the conviction that the vaccine
can also be used in this age-group.
As an additional medical benefit, QIV provided protection against severe influenza illness and
reduced the risk of influenza-associated AOM and ALRI. QIV also reduced other relevant clinical
outcomes in children, including medical examinations (2.3% in the QIV group vs. 5.6% in the placebo
group) and antibiotic use (1.7% in the QIV group vs. 4.2% in the placebo group). QIV had a similar
safety profile to those of TIV and placebo. No clinical concern was observed; QIV proved safe and well
tolerated in unvaccinated children aged 6–35 months [87].
5. Conclusions
The current virological situation and the difficulty in predicting which influenza B virus lineage
will be prevalent during the next influenza season have reduced immunological protection among
vaccinated individuals. Thus, it is evident that new immunization strategies are required; replacing TIV
with QIV could be an effective strategy, as suggested by the European Centre for Disease Prevention
and Control (ECDC) [96]. In this regard, QIV licensure can meet this specific immunization need,
and may be able to reduce influenza morbidity and influenza-associated mortality. The two groups
that could benefit most from QIVs may be children and adolescents, who are significantly affected by
influenza B viruses, and the elderly [32]. Chan’s group estimated that 60 out of every 1000 influenza
cases could be prevented by using QIV instead of TIV [32]. An estimate of the public health and
economic impact of QIV in comparison with TIV was performed in Europe by Uhart and colleagues [97];
this revealed that the use of QIV could considerably reduce both influenza cases and influenza-related
costs (evaluated as €15 million and €77 million saved from general practitioners’ consultations and
hospitalizations, respectively). Since 1968, the most widely-used influenza vaccine has been the
corresponding TIV, over 1.8 billion doses of which have been distributed in more than 120 countries.
This is the only influenza vaccine whose immunogenicity and clinical outcomes have been thoroughly
evaluated, even in pregnant women at any stage of pregnancy and their infants. Regarding the use of
Vaxigrip Tetra in pregnant women, a controlled randomized trial (GQM14; EudraCT: 2016-004763-40)
is currently ongoing in Finland with the aim to evaluate its immunogenicity and safety (in terms of
pregnancy and birth outcomes) in this high-risk group for influenza infection [98]. The quadrivalent
formulation, Vaxigrip Tetra, is well tolerated and has not given rise to any safety concerns.
If one additional B virus strain were included, Vaxigrip Tetra (QIV) could provide significantly
higher protection than the previously available TIV. Indeed, it eliminates the possibility of seasonal
mismatched B strains, as observed during the last decade [33] with regard to previous influenza
vaccines, without compromising protection towards influenza A. The immunogenicity and safety of
Vaxigrip Tetra has been widely investigated in all age-groups (children, adults, and elderly) and has
recently received EU authorization for its use in infants over 6 months of age. Vaxigrip Tetra not only
displays an immunogenicity profile similar to that of the corresponding TIV; it has also proved able to
induce a superior immune response towards the additional strain, without affecting immunogenicity
for the other three strains. By contrast, TIV has been shown to evoke limited cross-reactivity against
the missing B-lineage strain. In addition, the safety profile of Vaxigrip Tetra is equivalent to that of the
corresponding licensed TIV, and no clinical concerns have been noted. Investigations conducted in
children aged >6 months and in the elderly strongly support extending the use of Vaxigrip Tetra to
these high-risk groups, thereby significantly increasing protection against influenza.
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